About Insife
Insife is a company based in Copenhagen (Denmark) founded in 2017 by Martin Holm-Petersen was acquired by Qinecsa in March 2024. The company has 27 employees as of March 21, 2024. Insife offers products and services including HaloPV and GRIP. Insife operates in a competitive market with competitors including DrugCard, biologit, Beijing Dongxie Network, Sentrx and My Meds & Me, among others.
- Headquarter Copenhagen, Denmark
- Employees 27 as on 21 Mar, 2024
- Founders Martin Holm-Petersen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Insife India Private Limited
- Date of Incorporation 29 Nov, 2018
- Jurisdiction Bengaluru, Karnataka, India
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Insife
Insife offers a comprehensive portfolio of products and services, including HaloPV and GRIP.
Automates case intake and data management for drug safety processes.
Delivers intelligence on regulations across 165 countries.
People of Insife
Unlock access to complete
Funding Insights of Insife
Detailed funding history for Insife
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Insife
Insife has secured backing from 1 investor. Prominent investors backing the company include Qinecsa.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides pharmacovigilance technology and services for drug safety management globally.
|
Locked | Locked | Locked |
Investor details for Insife
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insife
Investment portfolio details for Insife
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Insife
Detailed financials for Insife
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Insife Comparisons
Peer comparison for Insife
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Insife
Insife operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DrugCard, biologit, Beijing Dongxie Network, Sentrx and My Meds & Me, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug pharmacovigilance solutions are provided for pharmaceutical industries.
|
|
| Locked | Locked | Locked |
AI-based solutions for drug pharmacovigilance are provided.
|
|
| Locked | Locked | Locked |
AI-based pharmacovigilance platform is developed for report analysis and monitoring.
|
|
| Locked | Locked | Locked |
Specialized pharmacovigilance software and services are developed and provided.
|
|
| Locked | Locked | Locked |
Adverse events and product quality are captured for life sciences.
|
|
| Locked | Locked | Locked |
Provider of a SaaS based regulatory data analysis and pharmacovigilance platform for life science industry
|
Detailed competitors of Insife
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Insife
Complete news archive for Insife
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insife
Insife was founded in 2017.
Insife is headquartered in Copenhagen, Denmark.
Martin Holm-Petersen is the current CEO of Insife. They have also founded this company.
As of Mar 21, 2024, the latest employee count at Insife is 27.
Annual revenue of Insife is $430.98K as on Mar 31, 2022.
Insife offers pharmacovigilance consulting services for pharma, biotech, and national agencies. They provide services for regulatory intelligence, PV agreements organizational entity management, risk management (documentscommitments), literature monitoring, program oversight (MSP MRP), scanning of websites and social media. Softwares for pharmacovigilance includes Argus safety database system, OBIEE analytical, TransformPV, etc. Demystifier is the software for clinical data standardization, HiLIT is a cloud-based integrated analytics platform, ClinINT is developed that collects, integrates and manage structured and unstructured clinical data.
Insife's top competitors include biologit, Sentrx and My Meds & Me.
Insife offers HaloPV and GRIP.
Insife has 1 investor. Key investors include Qinecsa.